Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
Full metadata record
|dc.identifier.citation||Food and Bioproducts Processing, 1995; 73(1):27-32||-|
|dc.description.abstract||A recombinant insulin-like growth factor analog (Long-R3–IGF-I, 19921) is currently produced for industrial use as a component in mammalian cell culture media. Gradually expanding markets require that the existing production process be modified to allow increased throughput. The process is therefore examined and the key bottleneck identified as the ion-exchange recovery of refolded peptide. Theoretically, process throughput can be significantly increased with minimum expense by increasing the refolding concentration and by concentrating the refolded peptide prior to ion-exchange recovery. Experimental studies into the effect of refolding concentration on peptide yield are described and the results fitted to a model of competing first– and second-order reactions. An increase in the refolding concentration is presently uneconomical, due to a reduction in the yield of correctly refolded protein. However, concentrating the refolded peptide by ultrafiltration proved feasible. Using this result, the outline of a semi-continuous de-bottlenecked process is described which is capable of increasing the throughput ten-fold without major purchase of new equipment.||-|
|dc.publisher||Institution of Chemical Engineers||-|
|dc.title||Studies into the scale-up of a process to produce biosynthetic insulin-like growth factor||-|
|Appears in Collections:||Aurora harvest 2|
Chemical Engineering publications
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.